- Home
- AXL vs KURA Comparison
AXL vs KURA Comparison
Compare AXL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- KURA
- Stock Information
- Founded
- AXL 1994
- KURA 2014
- Country
- AXL United States
- KURA United States
- Employees
- AXL N/A
- KURA N/A
- Industry
- AXL Auto Parts:O.E.M.
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AXL Consumer Discretionary
- KURA Health Care
- Exchange
- AXL Nasdaq
- KURA Nasdaq
- Market Cap
- AXL 501.9M
- KURA 492.9M
- IPO Year
- AXL 1999
- KURA N/A
- Fundamental
- Price
- AXL $4.19
- KURA $5.85
- Analyst Decision
- AXL Hold
- KURA Strong Buy
- Analyst Count
- AXL 7
- KURA 12
- Target Price
- AXL $6.07
- KURA $24.50
- AVG Volume (30 Days)
- AXL 2.9M
- KURA 1.3M
- Earning Date
- AXL 08-08-2025
- KURA 08-07-2025
- Dividend Yield
- AXL N/A
- KURA N/A
- EPS Growth
- AXL N/A
- KURA N/A
- EPS
- AXL 0.18
- KURA N/A
- Revenue
- AXL $5,929,300,000.00
- KURA $67,991,000.00
- Revenue This Year
- AXL N/A
- KURA $109.86
- Revenue Next Year
- AXL N/A
- KURA $107.90
- P/E Ratio
- AXL $23.82
- KURA N/A
- Revenue Growth
- AXL N/A
- KURA N/A
- 52 Week Low
- AXL $3.00
- KURA $5.41
- 52 Week High
- AXL $7.65
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- AXL 46.31
- KURA 40.44
- Support Level
- AXL $4.12
- KURA $5.56
- Resistance Level
- AXL $4.39
- KURA $7.17
- Average True Range (ATR)
- AXL 0.17
- KURA 0.38
- MACD
- AXL -0.03
- KURA -0.06
- Stochastic Oscillator
- AXL 23.53
- KURA 6.05
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.